Ionis Pharmaceuticals ($IONS) Insider Trading & Smart Money Activity
Ionis Pharmaceuticals, Inc. ($IONS) has 12 insider trades, 3 13F position changes and 3 analyst ratings on file. In the last 12 months on the open market, no insider bought and 3 insiders sold ($1.88M), net -$1.88M.
- Insider buyers (12 mo)
- 0
- Insider sellers (12 mo)
- 3
- Net insider $ (12 mo)
- -$1.88M
- Congress trades (12 mo)
- 0
- 13F moves on file
- 3
- Analyst ratings on file
- 3
IONS insider buying and selling by quarter
| Quarter | Insider buys | Insider sales | Congress buys / sales | 13F added / cut |
|---|---|---|---|---|
| Q1 2026 | 0 | 0 | 0 / 0 | 0 / 0 |
| Q2 2026 | 0 | 3 · $1.88M | 0 / 0 | 1 / 2 |
| Q3 2026 | 0 | 0 | 0 / 0 | 0 / 0 |
| Q4 2026 | 0 | 0 | 0 / 0 | 0 / 0 |
Insider buys and sales count open-market trades only (Form 4 codes P and S). Grants, option exercises and tax withholding are left out.
All IONS insider, congress, 13F and analyst activity
| Date | Source | Who | Action | Shares | Value / amount | ΔOwn | 1W | 1M | 6M | Filing | Story |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Insider | Eugene SchneiderEVP, Chf Clinical Develop Ofcr | Buy (Option exercise) | 26K sh | $1.58M | +2.5% | -31.1% | Read | ||||
| Insider | Brett MoniaChief Executive Officer | Sell (Option exercise) | 50K sh | +2.5% | -31.1% | — | |||||
| Insider | Brett MoniaChief Executive Officer | Buy (Option exercise) | 50K sh | $2.84M | +2.5% | -31.1% | — | ||||
| Insider | Joseph BaroldiEVP, Chief Business Officer | Sell (Open-market sale) 10b5-1 | 5.63K sh | $451.70K | +2.5% | -31.1% | — | ||||
| Insider | Joseph BaroldiEVP, Chief Business Officer | Buy (Option exercise) | 5.63K sh | $277.18K | +2.5% | -31.1% | Read | ||||
| Analyst | Leerink Partners | Reiterates to buy | PT $129 | +4.4% | -28.6% | Read | |||||
| Insider | Eric SwayzeEVP Research | Sell (Open-market sale) 10b5-1 | 10.60K sh | $839.47K | +4.4% | -28.6% | — | ||||
| Insider | Brett MoniaChief Executive Officer | Sell (Option exercise) | 21.07K sh | +4.4% | -28.6% | — | |||||
| Insider | Brett MoniaChief Executive Officer | Buy (Option exercise) | 21.07K sh | $686.95K | +4.4% | -28.6% | — | ||||
| Analyst | HC Wainwright | Reiterates to buy | PT $130 | +4.4% | -28.6% | Read | |||||
| Insider | Brett MoniaChief Executive Officer | Sell (Option exercise) | 14.56K sh | +3.5% | -26.1% | Read | |||||
| Insider | Brett MoniaChief Executive Officer | Buy (Option exercise) | 14.56K sh | $474.82K | +3.5% | -26.1% | Read | ||||
| Analyst | Leerink Partners | Reiterates to buy | PT $122 | +3.0% | -26.8% | Read | |||||
| Insider | Spencer Berthelsen | Sell (Open-market sale) 10b5-1 | 8K sh | $587.92K | +2.6% | -26.0% | Read | ||||
| Insider | Spencer Berthelsen | Buy (Option exercise) | 8K sh | $195.36K | +2.6% | -26.0% | — | ||||
| 13F | T. Rowe Price Investment Management | Reduced | -2.95M sh | $454.66M | +1.8% | -0.4% | — | ||||
| 13F | T. Rowe Price Investment Management | Reduced | -2.95M sh | $496.97M | +1.8% | -0.4% | — | ||||
| 13F | Baker Bros. Advisors | Added | +255.89K sh | $162.36M | +1.8% | -0.4% | — |
1W / 1M / 6M = how IONS moved from the trade or filing date.
Insider trading in IONS: who is buying and selling
| Insider | Role | Trades | Open-market net | Shares held | Last trade |
|---|---|---|---|---|---|
| Brett Monia | Chief Executive Officer | 6 | — | Jun 26, 2026 | |
| Joseph Baroldi | EVP, Chief Business Officer | 2 | -$451.70K | Jun 26, 2026 | |
| Eugene Schneider | EVP, Chf Clinical Develop Ofcr | 1 | — | Jun 26, 2026 | |
| Eric Swayze | EVP Research | 1 | -$839.47K | Jun 25, 2026 | |
| Spencer Berthelsen | 2 | -$587.92K | Jun 15, 2026 |
Institutions moving IONS (13F)
Analyst ratings on IONS
Frequently asked questions
Are IONS insiders buying or selling?
Over the last 12 months 0 insiders made 0 open-market purchases worth $0 and 3 insiders made 3 open-market sales worth $1.88M, a net -$1.88M.
What is the latest insider trade in IONS?
Eugene Schneider, EVP, Chf Clinical Develop Ofcr filed a buy (option exercise) of 26K sh worth $1.58M on Jun 26, 2026.
Which institutions changed their IONS positions?
Recent 13F filers moving the stock include T. Rowe Price Investment Management and Baker Bros. Advisors.
Other biotechnology stocks
Data comes from public SEC Form 4 and 13F filings and STOCK Act disclosures. Dates are the trade or filing date reported. This page is for research only and is not investment advice.
Get a text when insiders, Congress or big funds trade a stock.
Free. Reply STOP anytime.